Search Results - nsclc

3 Results Sort By:
Nanoparticle delivery of lung cancer therapeutic
Abstract: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in developed countries.  Despite the availability of several synergistic, targeted therapy regiments, the 5-year survival rate for NSCLC is only 15%.  The poor prognosis of NSCLS is due in part to limitations of current treatments, which do not trigger an immune...
Published: 5/22/2024   |   Inventor(s): Dennis Klinman, Takashi Sato (Unable To Locate)
Keywords(s): Immunotherapy, Nanoparticle, Non-small cell lung cancer, NSCLC
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
Non-invasive diagnostic and prognostic assay for early stage lung cancer
Abstract: In the United States alone, one of four cancer deaths occur from lung cancer and there are over 8 million individuals considered to be at high-risk due to cigarette smoking and other behaviors. It's well known that early detection of cancer significantly improves survival of this disease, however a lack of lung cancer screenings and analysis...
Published: 4/8/2024   |   Inventor(s): Curtis Harris, Ewy Mathe, Frank Gonzalez, Kristopher Krausz, Soumen Manna, Andrew Patterson, Majda Haznadar
Keywords(s): LDCT, LD-CT, liquid biopsy, low-dose computed tomography, Non-small cell lung cancer, NSCLC, Urine
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Diagnostics, Collaboration Sought > Licensing
Small Drug-like Molecules as Anticancer Agents for NSCLC
Project ID: D2013-04Background Lung cancer is the leading cause of cancer deaths in the United States. More than 80% of the lung cancer deaths belong to non-small cell lung cancer (NSCLC). The 5-year survival rate of patients with NSCLC is about 16% with current treatments including surgery, radiation and other classic chemotherapeutic agents and targeted...
Published: 6/18/2024   |   Inventor(s): Liyanaaratchige Tillekeratne, William Taylor, Sara Fedorka
Keywords(s): Anticancer, Hydroxyurea, NSCLC, Taxol
Category(s): Oncology